Navigation Links
Long-Term Statin Use Won't Raise Cancer Risk: Study
Date:11/10/2010

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, Nov. 10 (HealthDay News) -- Long term use of cholesterol-lowering drugs called statins does not increase the risk of cancer and may even decrease users' risks for lymphoma, melanoma and endometrial tumors, a new study finds.

Studies have shown that the short-term use of statins -- drugs such as Crestor, Lipitor and Zocor -- has little effect on the risk of developing cancer, but less was known about the their use over the long term.

But the new 10-year study suggests that "even long-term statin use is unlikely to increase the risk of common cancers," according to lead researcher Eric J. Jacobs, strategic director of pharmacoepidemiology at the American Cancer Society.

Jacobs was scheduled to present the results Tuesday at a cancer prevention-focused meeting of American Association for Cancer Research in Philadelphia.

For the study, Jacobs's team collected data on more than 133,000 participants in the Cancer Prevention Study II Nutrition Cohort. These people completed questionnaires that included questions about a variety of lifestyle and medical factors, including their use of statins.

Over 10 years of follow-up, 15,000 participants developed cancer.

However, the use of a statin for 5 years or more did not affect the risk of developing cancer of the bladder, breast, colon/rectum, lung, pancreas, prostate or kidneys, the researchers found. In fact, long-term statin use appears unlikely to substantially increase or decrease overall cancer risk, the researchers noted.

But there was other good news. Compared to people who did not take the medications, 5 or more years of statin use was associated with a lowering of risk for melanoma, endometrial cancer and non-Hodgkin lymphoma, the team found. For example, odds for endometrial tumors fell by 39 percent among long-term statin users, while the risk for melanoma dropped by 19 percent, the study found.

The lower risk of endometrial cancer and melanoma had not been seen in prior studies, Jacobs said.

Still, "the results of lower risk of melanoma, endometrial cancer and non-Hodgkin lymphoma need to be interpreted cautiously," Jacobs said.

The study was not conclusive, and according to the researchers, the findings deserve further investigation. And experts note that research presented at conferences typically does not undergo the kind of scrutiny given to studies published in leading journals.

One expert took comfort from the results.

"Over the years the issue of statins and cancer has always been there," said Dr. Ronald Goldberg, professor of medicine, biochemistry and molecular biology at the University of Miami Miller School of Medicine. "It's been demonstrated that the lower the LDL ["bad"] cholesterol, the higher the risk of cancer. And because statins lower LDL there was always the question: Are they promoting that relationship?"

Now, the bulk of the evidence suggests that there is no effect of statins in increasing the risk of malignancy, Goldberg said. "By and large, I think the news is reassuring," he said.

More information

For more information on statins, visit the U.S. National Library of Medicine.

SOURCES: Eric J. Jacobs, Ph.D., strategic director, pharmacoepidemiology, American Cancer Society; Ronald Goldberg, M.D., professor of medicine, biochemistry, and molecular biology, University of Miami Miller School of Medicine; Nov. 9, 2010, presentation, American Association for Cancer Research Frontiers in Cancer Prevention Research conference, Nov. 7-10, 2010, Philadelphia


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Spending Months in Space May Cause Long-Term Bone Loss
2. Protein Differences May Explain Long-Term HIV Control
3. Childhood cancer survivors face long-term risk of GI complications, study finds
4. A dry AMD treatment?; some long-term diabetics escape PDR
5. Surgery offers long-term survival for early stage prostate cancer patients
6. Results of the placement of multiple endoscopic stents for postoperative biliary strictures remains excellent after long-term follow-up
7. Long-Term Use of Bone Drugs May Be Linked to Esophageal Cancer
8. Short-Term Overeating Could Make Long-Term Weight Loss Tougher
9. Long-Term Type 1 Diabetes Survivors Give Clues to the Disease
10. Drug-eluting stents confirmed safe, effective for long-term use
11. CLASS Act analysis reveals Americas long-term care future
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Long-Term Statin Use Won't Raise Cancer Risk: Study
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy ... health literacy software tool, and the Cancer Patient Education Network (CPEN), an independent ... today announce a new strategic alliance. , As CPEN’s strategic partner, HLI ...
(Date:10/12/2017)... Miramar, FL (PRWEB) , ... October 12, 2017 ... ... is presenting the latest in wound care advancements to physician colleagues, skilled nursing ... lecture is titled, "Navigating the Treacherous Waters of Wound Care." , "At many ...
(Date:10/12/2017)... CHICAGO (PRWEB) , ... October ... ... innovator in life sciences content management, presents its enhanced Pepper Flow promotional ... Oct. 16 -18, 2017. Pepper Flow’s increased insight-driven capabilities help marketers streamline ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , the ... chains, has published the first annual edition of its Global CSR Risk ... 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly ... ... Performance Index ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
Breaking Medicine Technology: